Cognitive clarity in colon surgery: The dexmedetomidine advantage

Colon cancer is one of the most prevalent cancers globally, especially in the older age group. A large number of older patients undergoing surgery for colon cancer suffer from postoperative cognitive dysfunction (POCD). The trial by Bu et al demonstrated that dexmedetomidine (Dex) significantly reduced the incidence of POCD compared to placebo in individuals undergoing colon cancer surgery. Additionally, better cerebral oxygenation and lower cerebral injury markers were reported with the use of Dex. The trial has some limitations, such as a single-center design and a smaller sample size, and further studies with larger patient populations and robust multi-center designs are warranted to establish these findings.